Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Skuldtech Secures EUR 1 Million to Develop New Diagnostics for Alzheimer's Disease

Published: Wednesday, September 11, 2013
Last Updated: Wednesday, September 11, 2013
Bookmark and Share
Skuldtech and AB Science to renew their collaboration agreementto bring to market a new treatment for Alzheimer's disease.

Skuldtech announces that it has secured EUR 1 million in funding from Bpifrance (French public financing structure) as part of a project on Alzheimer's disease that has received funding of EUR 8.6 million in total. The program is planned to last for four years, with the first results expected in 2018.
 
Skuldtech has joined forces with AB Science for this program, with the aim of developing a new therapy for the treatment of Alzheimer's disease. As part of the program, Skuldtech will develop a companion diagnostic for AB Science's masitinib molecule and a diagnostic for the validity of cognitive tests and tests to predict the progression of Alzheimer's disease.

Using blood samples taken as part of the Phase III trial of masitinib in Alzheimer's disease, Skuldtech will identify the blood biomarkers that will help make simple, reliable diagnostic tests available as a matter of routine. This will result in treatments that can be tailored to the patient and the ability to monitor sufferers as their disease progresses. The clinical trial of masitinib was launched in Europe and other countries in May 2013. It expects to recruit a total of 400 patients. Blood samples from these patients will contribute to the development of a companion diagnostic by making it possible to identify those individuals most likely to benefit from the treatment.
 
This approach has already proven successful in the development of a new treatment for pancreatic cancer that combines gemcitabine and masitinib, where Skuldtech identified new biomarkers predicting a favorable response to treatment. The results of this clinical study led to an application to the European Medicines Agency for Marketing Authorization (MA) for masitinib in combination with companion biomarkers.
 
Using further blood samples, Skuldtech will also develop a diagnostic for the validity of cognitive tests and tests predicting the progression (slow or rapid) of Alzheimer's disease.
 
This project builds on Skuldtech's recent success in identifying blood biomarkers associated with a cognitive score. The company identified two sets of new blood markers, each associated with two trisomy 21 patient populations with low and high IQs respectively. The results of this study were published in the European Journal of Human Genetics in February 2013 (i). By describing the blood transcriptional profile of each group, Skuldtech identified specific biomarkers corresponding to a level of response in cognitive tests. The company hopes to emulate this result in the Alzheimer's disease program.
 
Skuldtech is keen to use the funding to capitalize on its broadband sequencing-based technological platform, pairing it with proprietary bioinformatics and biostatistics programs to measure and confirm the stage of progression of Alzheimer's disease.
 
“This new partnership to work on Alzheimer's disease will strengthen Skuldtech's position in the field of personalized medicine and in the development of companion diagnostics associated with new treatments in phases of clinical trials,” said Didier Ritter, CEO, Skuldtech. “As well as bringing new diagnostics to market, we are also open to similar partnerships with other biotech companies or with pharmaceutical laboratories.”
 
Alzheimer's is the most frequently occurring neurodegenerative disease in the world, affecting around 6 per cent of over-65s. In the US, it is the sixth most common cause of mortality in the population.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Skuldtech Identifies New Predictive Markers for Pancreatic Cancer Survival
The companion diagnostic developed by Skuldtech from these biomarkers will make it possible to identify patients most likely to benefit from this new treatment.
Thursday, January 31, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Stem Cells Growing 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
The Genetics of Blood Pressure
Researchers have identifed areas of the genome associated with blood-pressure including 17 previously unknown loci.
Mystery of Early Embryonic Development Solved
Breakthrough genomics technique can be used to map epigenetic marks across the genome using fewer cells and will benefit cancer research
Mouse Genes Guiding Precision Medicine
Research of the mouse genome has identified hundreds of essential-to-life genes from the 1751 genes studied.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Schizophrenia Drug Response Dictated by Genes
Study suggests schizophrenia drug may decrease negative symptoms for people with certain gene variant.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!